BioScience Health Innovations (BHIC) Gross Margin (2023 - 2026)

BioScience Health Innovations (BHIC) has 4 years of Gross Margin data on file, last reported at 64.66% in Q1 2026.

• Gross Margin for Q1 2026 came in at 64.66%, down 837.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 54.29% (down 1621.0% YoY), and the FY2025 annual result was 56.97%, down 1398.0% from the prior year.
• Gross Margin grew to 64.66% in Q1 2026 per BHIC's latest filing, from 36.36% in the prior quarter.
• Over five years, Gross Margin peaked at 86.33% in Q2 2023 and troughed at 36.36% in Q4 2025.
• A 4-year average of 71.15% and a median of 74.13% in 2024 frame the typical range for Gross Margin.
• On a YoY basis, Gross Margin climbed as much as 75 bps in 2024 and fell as far as 2234 bps in 2024.
• A 4-year view of Gross Margin shows it stood at 77.89% in 2023, then retreated by 29 bps to 55.56% in 2024, then plunged by 35 bps to 36.36% in 2025, then soared by 78 bps to 64.66% in 2026.
• Business Quant data shows BHIC's Gross Margin at 64.66% in Q1 2026, 36.36% in Q4 2025, and 61.71% in Q3 2025.